Item type |
デフォルトアイテムタイプ_(フル)(1) |
公開日 |
2023-03-18 |
タイトル |
|
|
タイトル |
Chemical synthesis of Maxadilan, a non-mammalian potent vasodilatory peptide consisting of 61 amino acids with two disulfide bridges, and its related peptides |
|
言語 |
en |
作成者 |
Nokihara, Kiyoshi
Yasuhara, Tadashi
Nakata, Yoshihiro
Lerner, Ethan A.
Wray, Victor
|
アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
権利情報 |
|
|
権利情報 |
Copyright (c) 2007 Springer "The original publication is available at www.springerlin.com" |
主題 |
|
|
主題Scheme |
Other |
|
主題 |
vasodilator |
主題 |
|
|
主題Scheme |
Other |
|
主題 |
maxadilan |
主題 |
|
|
主題Scheme |
Other |
|
主題 |
PAC1 receptor |
主題 |
|
|
主題Scheme |
Other |
|
主題 |
disulfide isomer |
主題 |
|
|
主題Scheme |
Other |
|
主題 |
highly efficient solid-phase synthesis |
主題 |
|
|
主題Scheme |
Other |
|
主題 |
difficult sequence |
主題 |
|
|
主題Scheme |
Other |
|
主題 |
melanophore assay |
主題 |
|
|
主題Scheme |
NDC |
|
主題 |
490 |
内容記述 |
|
|
内容記述 |
A potent and persistent non-mammalian derived vasodilator, maxadilan (Maxa) consists of 61 amino acids with two disulfide linkages and acts as an agonist of the type I receptor of pituitary adenylate cyclase activating polypeptide (PACAP), although there is very little sequence similarity. The total chemical syntheses of Maxa, its disulfide isomers and various fragments have been performed successfully by highly efficient solid-phase peptide synthesis (SPPS). A "difficult sequence", envisaged in the middle region of Maxa, could be overcome by improved synthesis protocols. After assembly peptides were liberated from the resin by cleavage. Peptides having disulfide(s) were purified by two steps of preparative HPLC using cation exchange followed by reverse phase columns. Purified peptides were characterized by HPLC, Edman-sequencing, amino acid analysis and mass spectrometry in addition to disulfide form determination. The peptides obtained were used for recognition studies by the melanophore assay to confirm the native disulfide form. Peptide libraries related to Maxa, produced in the present study, will be useful for the elucidation of the structural requirements of Maxa for interaction with the PACAP type 1 receptor (PAC1). |
|
言語 |
en |
出版者 |
|
|
出版者 |
Springer |
言語 |
|
|
言語 |
eng |
資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
出版タイプ |
|
|
出版タイプ |
AO |
|
出版タイプResource |
http://purl.org/coar/version/c_b1a7d7d4d402bcce |
関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1007/s10989-007-9097-9 |
関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
http://dx.doi.org/10.1007/s10989-007-9097-9 |
収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1573-3149 |
収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12077391 |
開始ページ |
|
|
開始ページ |
377 |
書誌情報 |
International Journal of Peptide Research and Therapeutics
International Journal of Peptide Research and Therapeutics
巻 13,
号 1-2,
p. 377-386,
発行日 2007-06
|
旧ID |
20570 |